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Abstract: Microalgae have the ability to synthetize many compounds, some of which have been
recognized as a source of functional ingredients for nutraceuticals with positive health effects.
One well-known example is the long-chain polyunsaturated fatty acids (PUFAs), which are essential
for human nutrition. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the two
most important long-chain omega-3 (ω-3) PUFAs involved in human physiology, and both industries
are almost exclusively based on microalgae. In addition, algae produce phytosterols that reduce
serum cholesterol. Here we determined the growth rates, biomass yields, PUFA and sterol content,
and daily gain of eight strains of marine cryptophytes. The maximal growth rates of the cryptophytes
varied between 0.34–0.70 divisions day−1, which is relatively good in relation to previously screened
algal taxa. The studied cryptophytes were extremely rich in ω-3 PUFAs, especially in EPA and
DHA (range 5.8–12.5 and 0.8–6.1 µg mg dry weight−1, respectively), but their sterol concentrations
were low. Among the studied strains, Storeatula major was superior in PUFA production, and it also
produces all PUFAs, i.e., α-linolenic acid (ALA), stearidonic acid (SDA), EPA, and DHA, which is
rare in phytoplankton in general. We conclude that marine cryptophytes are a good alternative for
the ecologically sustainable and profitable production of health-promoting lipids.
Keywords: microalgae; polyunsaturated fatty acids; omega-3; omega-6; sterols; functional foods;
nutraceuticals
1. Introduction
Consumers’ growing awareness of healthy products has promoted the development of novel
natural sources of functional ingredients. Microalgae have been suggested to be among the most
promising sources, since they can be used to produce many kinds of biomolecules with high
nutraceutical value [1–3]. Microalgae can be grown in controlled conditions, allowing the production of
biomass with a constant biochemical composition and eliminating the risk of chemical contamination
of the biomass. Thus, the biotechnology of microalgae has gained considerable importance in
recent decades.
To date, many commercial nutraceuticals, dietary supplements, and functional ingredients as
well as pigments are produced using green algae, e.g., Chlorella, and cyanobacteria, e.g., Spirulina.
These taxa are fast growing and rich in, for example, amino acids, but they are low in some of the
most desirable biomolecules such as long-chain polyunsaturated omega-3 fatty acids (ω-3 PUFAs),
which are a specific group of polyunsaturated fatty acids in which the first double bond is located
between the third and fourth carbon atom counting from the methyl end of the fatty acid. Only plants
can synthesize PUFAs, which means that consumers must obtain them from their diet [4].
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The four types of ω-3 PUFAs mostly involved in human physiology are α-linolenic
acid (ALA; 18:3:ω3), stearidonic acid (SDA, 18:4:ω3), eicosapentaenoic acid (EPA; 20:5:ω3),
and docosahexaenoic acid (DHA; 22:6:ω3). The long-chain EPA and DHA can be obtained only
from certain organisms, mainly of aquatic origin, whereas all terrestrial plants produce and contain
fairly high amounts of ALA, which is the precursor to theω-3 series fatty acids (FAs) [5]. The human
body cannot produce short-chainω-3 on its own, and converts the short-chainω-3 to the long-chain
versions, especially DHA, inefficiently (i.e., only 3–4% is converted) [4]. Thus, EPA and DHA are
often determined as essential dietary nutrients. They are both needed for normal metabolism,
and they have been implicated in the reduction of cardiovascular diseases like arrhythmia, stroke,
and high blood pressure, and can ameliorate renal diseases, depression, dementia, rheumatoid arthritis,
and asthma, and are essential for normal fetal brain development as well as growth and development
of infants/children [1,6].
The ω-6 PUFAs have been shown to promote health in some cases, e.g., reduce nerve pain of
diabetic patients and help boys with symptoms of attention deficit hyperactivity disorder (ADHD) [7,8];
however, excess dietary gain of ω-6 PUFAs is known to promote cardiovascular disease, cancer,
and inflammatory and autoimmune diseases in humans [9]. In the Western diet, ω-6 PUFA
consumption has become progressively much higher than that of ω-3 PUFA due to increased
consumption of vegetable oils rich in linoleic acid (LA; 18:2ω6; precursor of the long chain ω-6
FAs) [10]. The optimal dietaryω-6/ω-3 ratio should be around 1-4:1, but in the Western diet it varies
between 10:1 and 20:1 [11,12]. This is significant, since both ω-6 and ω-3 elongation need the same
enzymes and, thus, in humans, the excess consumption ofω-6 FAs reduces the already low conversion
rate of short-chainω-3 ALA to long-chain EPA and DHA by 40–50% [13].
So far, fish oil has been the main commercial source of EPA and DHA, but alternative sources are
needed since the global consumer needs cannot be satisfied by the current global fish stock harvests,
and also the practice of using fish as feed at fish farms is nonsustainable. Furthermore, fish oil is not
suitable for vegetarians or people allergic to fish, it has an odor unpleasant to some people, and it
may contain lipid-soluble environmental pollutants. Fish oil quality also varies depending on the fish
species, season, and geographical location [14]. Like humans, fish obtain EPA and DHA from their
diet, basically from microalgae, some of which could be used in commercial PUFA production.
Besides PUFAs, many algae are also rich in other lipids, such as phytosterols. Phytosterols have
chemical structures similar to cholesterol, but they are effective in reducing serum cholesterol levels,
and they may also prevent Alzheimer’s disease, suppress the growth of colonic tumors, and have
beneficial effects on prostate disorders [15,16]. Stigmasterol, campesterol, and sitosterol are the main
molecular species of phytosterols, and stigmasterol is claimed to be the most valuable of these three
due to its health-promoting benefits [17]. Phytosterols can be found both in terrestrial and aquatic
plants and algae. Similar toω-3 PUFAs, dietary consumption is the only source of phytosterols found
in plasma of humans [18].
Even though microalgae are potentially very promising sources of lipids, the present challenge
is to find an economically viable way to use them for lipid production, and searching for the most
suitable species/strains plays an important role in this. Currently, Nannochloropsis (eustigmatophyte)
species are suggested to be among the most promising EPA and DHA producers for commercial
applications [2,19]. However, many microalgae are known to be able to accumulate lipids in high
amounts, and high EPA and DHA concentrations have been detected in both marine and fresh waters
in cryptophytes, dinoflagellates, and diatoms [20]. These three groups represent distinct phylogenetic
branches in the eukaryotic tree of life relative to green algae [21,22], and, thus, likely produce unique
cocktails of nutraceuticals.
Due to their high PUFA, sterol, and amino acid concentrations, the nutritional value of
cryptophytes has been proven to be of utmost importance in aquatic food webs [1,23–25]. This suggests
that cryptophyte algae could offer a potential source of lipids also for nutraceutical purposes.
There are already several publications reporting high PUFA concentrations in cryptophytes; however,
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most of these studies do not report the total amounts of FAs per biomass but only PUFA percentages of
the total FAs [1,26–28]. Similarly, most studies investigating FA content and composition in microalgae
do not report growth rates. This may give the wrong impression of their potential in profitable
PUFA production. Most cryptophytes are known to grow fairly slowly (growth rates well below
0.8 div. day−1) [27,29,30], which may hinder their usability in commercial production. However,
in suitable conditions some strains are reported to have higher growth rates (e.g., 1.2 div. day−1) [31].
The cell size of most cryptophyte species is small (below 500 µm3), and they do not possess heavy
cell wall structures, which means that the cell biomass is low compared with that of many diatoms
and dinoflagellates. However, due to the lack of recalcitrant cell wall, cryptophytes are easier to
break and process further for commercial purposes than diatoms, dinoflagellates, or, for example,
Nannochloropsis [32]. Since the cultivation of marine algae has the benefits of using non-potable water
and non-arable land, we chose to focus on marine cryptophytes in this study. We analyzed the PUFA
and sterol contents of eight marine cryptophyte strains and estimate their usability (e.g., growth rate
and biomass production) for commercial lipid production.
2. Results and Discussion
2.1. Growth and Biomass Production
As expected, all species showed moderate growth rates between 0.34–0.70 div. day−1 in the
exponential growth phase (Table 1). However, the growth rates were very well comparable with the
ones detected for Nannochloropsis species, (0.04–0.60 div. day−1) [19]. Similarly, the observed growth
rates were competitive with strains of polar and temperate microalgae, including the prymnesiophyte
Emiliania huxleyi, prasinophyte Pyramimonas sp., and the raphidophyte Fibrocapsa japonica. The diatoms
Chaetoceros brevis and Thalassiosira weissflogii have been suggested for EPA and DHA production
by Bolen et al. [33] and also have lower growth rates (range 0.14–0.49 div. day−1), as do tropical
Nannochloropsis sp., Isochrysis sp., and Tetraselmis sp., which have been suggested for scale-up
production by Huerlimann et al. [34] (range 0.10–0.41 div. day−1). The daily volumetric biomass
yields of the cryptophyte strains differed remarkably, being highest in Chroomonas mesostigmatica
and Storeatula major (3.40 and 3.23 mg dry weight (DW) L−1 day−1) and lowest in Hemiselmis sp.
(0.28 mg DW L−1 day−1; Table 1). In terms of biomass production, the studied cryptophytes were not
competitive with Nannochloropsis species or commercially grown green algae, which can reach 10–100
times higher volumetric yields [35,36]. However, it needs to be kept in mind that, unlike Nannochloropsis
and many other algae, cryptophytes do not have strong and heavy cell wall structures, which would
also increase their cellular biomass. Thus, the comparisons of biomass yields between different algal
classes can be rather misleading. Furthermore, we did not try to optimize the growth rates or biomass
production of cryptophytes in this study, and thus cannot fully conclude the inferiority of cryptophytes
in terms of biomass production.
Table 1. The studied cryptophyte strains, their codes in culture collection, growth rates (divisions day−1)
and volumetric biomass yields (mg dry weight L−1 day−1). Different letters (a–f) denote significant
differences (ANOVA p < 0.05) between strains.
Species Code in Culture Collection Max. Growth Rate * Dry Weight (mg L−1 Day−1) ◦
Chroomonas mesostigmatica CCMP/NCMA 1168 0.65 (0.03) abc 3.40
Guillardia theta CCMP/NCMA 2712 0.66 (0.04) a 0.56
Hemiselmis sp. NRC5 0.70 (0.01) abcd 0.28
Proteomonas sulcata CCMP/NCMA 704 0.65 (0.01) abcd 1.47
Rhodomonas salina CCMP/NCMA 757 0.51 (0.01) bcde 2.79
Storeatula major SM or G 0.48 (0.03) bcde 3.23
Teleaulax acuta SCCAP K-1486 0.34 (0.01) f 1.05
Teleaulax amphioxeia GCEP01 0.55 (0.03) ab 2.05
* Detected after 4 days for C. mesostigmatica, 5 days for T. amphioxeia, Hemiselmis sp. and R. salina, and 7 days for
G. theta, T. acuta, P. sulcata and S. major. ◦ Detected after 5 days for C. mesostigmatica, 7 days for T. amphioxeia, S. major
and R. salina, and after 9 days for G. theta, T. acuta, P. sulcata and Hemiselmis sp.
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2.2. Polyunsaturated Fatty Acids
The proportion ofω-3 PUFAs (73.9± 7.0% of all FAs) was high in all of the studied strains, which is
in accordance with previous studies on cryptophytes and very competitive compared with microalgae
in general [26–28,37]. The highestω-3 PUFA proportions were found in S. major (81.1 ± 0.3% of all FA)
and Proteomonas sulcata (80.3 ± 1.9% of all FA). These two strains together with Guillardia theta and
Hemiselmis sp. also had the highest amount ofω-3 PUFAs in proportion to dry weight (4.9 ± 0.6% of
DW; Table 2).
The contribution of the short-chain ALA (average 51.1 ± 7.0% of all FAs) and SDA
(average 21.0 ± 5.8% of all FAs) varied a little between species, but did not differ statistically between
them. However, the proportion of long-chain EPA (average 19.1 ± 4.6% of all FAs) varied significantly
between the strains, as also did DHA (average 8.8 ± 4.9% of all FAs; Table 2). The studied marine
species had higher EPA and DHA proportions than has been previously found in the brackish
cryptophyte Rhodomonas baltica by Patil et al. [35] (EPA 13.1% and DHA 0.6% of all FAs). In comparison
to freshwater species, marine cryptophytes had equal amount of EPA, but more DHA than freshwater
strains [24,25]. The combined percentage of EPA and DHA is important for commercial purposes.
Together the EPA and DHA of the studied marine cryptophytes represented 20.8 ± 6.7% of all FAs,
which is competitive to the already commercially employed algae or species suggested as suitable
for commercial EPA and DHA production (EPA + DHA range 5–57% of total FAs) [2,3]. Furthermore,
the contribution of EPA and DHA was similar to the reported values of Nannochloropsis sp. (26.7%)
that has so far been considered to be one of most promising strains for commercial EPA and DHA
production [2]. The advantage of marine cryptophytes is that they contain a high proportion of both
EPA and DHA, whereas Nannochloropsis species contain mainly EPA [34].
The studies dealing with algal FA production often report results as proportions of PUFAs or total
FAs as we also did above. This makes it easy to compare between the strains, but does not actually tell
anything about the true gain of the FAs. Thus, we calculated the synthesized amount of FAs and per
volume per day (µg L−1 day−1). When calculated this way, S. major and C. mesostigmatica were the best
producers of ALA (45± 1.1 µg L−1 day−1; Table 3), even though the highest ALA content (2.6% of DW)
was found in Hemiselmis sp. Both S. major and C. mesostigmatica produced up to 10 times more ALA
daily than any other strain. Similarly, the SDA content was highest in the S. major (2.4 ± 0.01% of DW)
followed by C. mesostigmatica and G. theta. When taking into account the time and volume, S. major and
C. mesostigmatica were also the two most efficient producers of SDA (76 ± 3.3 µg L−1 day−1; Table 3),
whereas the SDA gain was lowest in G. theta. Due to the four double bond structure of SDA, it does not
require the rate-limiting enzyme desaturase to convert to EPA in humans, which means that dietary
SDA is a better precursor of EPA than ALA [38,39]. Thus, in addition to high EPA, the high SDA
content even further increases the value of certain cryptophytes as potential commercial sources of
ω-3 PUFAs. However, purely as SDA producers, algae compete with, e.g., soy that can be used for
enriched SDA oil production [39].
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Table 2. The ω-3 fatty acid (FA) contents in mg dry weight (DW) (µg FA in mg DW) and proportions (%) as well as the EPA/DHA ratios of the studied cryptophytes
and some other algae suggested for commercial lipid production (values derived from literature). ALA = α-linolenic acid (18:3:ω3), SDA = stearidonic acid (18:4:ω3),
EPA = eicosapentaenoic acid (20:5:ω3), DHA = docosahexaenoic acid (22:6:ω3). Different letters (a–g) denote significant differences (ANOVA p < 0.05) between strains.
The culture collection codes of the cryptophyte strains can be found in Table 1. Standard deviations for these FAs are shown in Supplemental Table S1.
Species Totalω-3 µgFA in Mg DW
ω-3%
of All FAs
ALA µg FA
in Mg DW
ALA% of
ω-3 FAs
SDA µg FA
in Mg DW
SDA% of
ω-3 FAs
EPA µg FA
in Mg DW
EPA% of
ω-3 FAs
DHA µg FA
in Mg DW
DHA% of
ω-3 FAs
EPA/DHA
Ratio
EPA + DHA%
of All FA
Chroomonas mesostigmatica 45.5 abcd 71.1 c 13.5 a 60.3 21.7 a 17.4 9.3 a 20.5 d 0.8 b 1.7 g 11.6 a 15.8 c
Guillardia theta 47.8 ac 65.4 b 19.7 a 56.7 19.5 ab 25.4 7.1 ab 14.9 a 1.4 b 3.0 e 5.1 b 11.7 d
Hemiselmis sp. 58.8 † 70.1 † 26.2 † 53.2 16.8 † 20.5 12.5 † 21.2 f 3.0 † 5.1 † 4.2 † 18.5 b
Proteomonas sulcata 48.2 bc 80.3 a 16.4 a 58.5 19.4 ab 16.2 6.1 ab 12.7 e 6.1 a 12.6 b 1 c 20.4 b
Rhodomonas salina 33.7 abd 64.2 b 8.6 b 48.8 15.4 b 22.8 5.8 b 17.2 g 3.8 c 11.2 c 0.5 d 18.2 bc
Storeatula major 51.4 abc 81.1 a 21.5 d 41.9 24.3 a 32.1 8.2 ab 16.0 g 5.2 ac 10.0 d 1.6 c 21.1 b
Teleaulax acuta 25.3 d 79.6 a 3.7 c 46.2 11.3 c 13.4 6.6 ab 26.0 c 3.6 c 14.3 a 1.8 c 32.1 a
Teleaulax amphioxeia 36.0 abcd 79.6 a 7.0 b 43.3 15.8 b 20.5 8.5 ab 23.6 b 4.6 ac 12.7 b 1.8 c 28.9 a
Nannochloropsis spp. (eustigmatophyte) * 7.7–30.8 [34] 23.4–28 [2] <0.06 [34] 26.7 [2]
Nitzschia spp. (diatom) * 3–9.2 [26]
Skeletonema spp. (diatom) * 16.3–17.6 [26]
Isochrysis spp. (prymnesiophyte) * 30.4–48.1 [26,34]
Tetraselmis sp. (chlorophyte) * 8.4–31.3 [34]
Dunaliella salina (chlorophyte) * 21.4 [2]
Chroothece richteriana (rhodophyte) * 29.4 [37] 15.9 [37]
† Could not be statistically tested. * Values from literature.
Table 3. The daily gain of ω-3 and ω-6 fatty acids and sterols (µg L−1 day−1) when produced with the studied cryptophytes. ALA = α-linolenic acid (18:3:ω3),
SDA = stearidonic acid (18:4:ω3), EPA = eicosapentaenoic acid (20:5:ω3), DHA = docosahexaenoic acid (22:6:ω3). LA = linoleic acid (18:2ω6), ARA = arachidonic acid
(20:4ω6), DPA = docosapentaenoic acid (22:5ω6). Different letters (a–d) denote significant differences (ANOVA p < 0.05) between strains. The culture collection codes
of the cryptophyte strains can be found in Table 1.
Species ALA
µg L−1 Day−1
SDA
µg L−1 Day−1
EPA
µg L−1 Day−1
DHA
µg L−1 Day−1
ω-3
µg L−1 Day−1
LA
µg L−1 Day−1
ARA
µg L−1 Day−1
DPA
µg L−1 Day−1
ω-6
µg L−1 Day−1
Sterols
µg L−1 Day−1
Chroomonas
mesostigmatica 45.93
a 73.83 a 31.64 a 2.72 c 154.81 a 7.83 b 0.34 b 0.34 b 28.92 b 4.36 a
Guillardia theta 11.00 b 10.89 c 3.96 e 0.78 d 26.69 c 1.84 c - 1.17 a 3.13 c 0.37 c
Hemiselmis sp. 7.28 † 4.66 † 3.47 † 0.83 † 16.34 † 0.72 † - - 1.14 † 0.43 †
Proteomonas sulcata 24.08 c 28.49 b 8.96 c 8.96 b 70.77 b 1.03 cd 0.44 b 0.59 ab 2.50 c 1.04 bc
Rhodomonas salina 23.95 c 42.89 b 16.16 b 10.58 b 93.87 b 15.32 a 4.46 a 0.84 a 26.74 b 2.73 b
Storeatula major 44.26 a 78.50 a 26.49 ab 16.8 a 166.04 a 5.49 b 0.65 b - 43.29 a 3.10 ab
Teleaulax acuta 3.89 d 11.87 c 6.93 d 3.78 c 26.57 c 0.11 d - - 0.21 d 0.37 c
Teleaulax amphioxeia 14.35 bc 32.39 b 17.43 b 9.43 b 73.8 b 1.85 c - - 2.05 c 0.92 c
† Could not be statistically tested.
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The content of EPA was highest (1.1 ± 0.2% of DW) in Hemiselmis sp. and C. mesostigmatica,
which is more than previously found in R. baltica or Oocystis sp. (0.11–0.4% of DW) [35], but less
than found from freshwater cryptophytes [24,25]. In relation to gain, S. major and C. mesostigmatica
were the two most efficient EPA synthesizers (29 ± 3.6 µg L−1 day−1), and their EPA gain was
double compared with those of the second-best strains, i.e., Teleaulax amphioxeia and Rhodomonas salina
(17 ± 0.9 µg L−1 day−1). The DHA content was highest (0.5± 0.08% DHA of DW) in P. sulcata, S. major
and T. amphioxeia. Their results were similar to previous measurements of freshwater strains, but higher
than found in brackish strains [25,35]. However, when calculated as daily gain, C. mesostigmatica was
shown to be a poor DHA producer (2.7 ± 0.2 µg L−1 day−1), whereas S. major was able to synthesize
high amounts of DHA (17 ± 0.2 µg L−1 day−1). Also, P. sulcata, R. salina and T. amphioxeia were better
DHA producers (9.7 ± 0.8 µg L−1 day−1) than C. mesostigmatica. Thus, among all studied strains,
S. major seems to be the superior species for ALA, SDA, EPA, and DHA production.
In commercially available food supplements, the EPA/DHA ratios are around 1.5 [40]. However,
the optimal EPA/DHA ratios have not been rigorously examined, and, thus, it is not known if this is
the most desirable ratio. Most of the studied cryptophytes had a similar or slightly higher EPA/DHA
ratios compared to established commercial products (Table 2), while the highest was observed in
C. mesostigmatica (EPA/DHA = 11.6) and lowest in R. salina (EPA/DHA 0.5).
The proportions of ω-6 PUFAs of all FAs varied greatly between strains, and was highest
(19.8 ± 0.1% of all FAs) in R. salina and lowest (0.7 ± 0.01% of all FAs) in Teleaulax acuta (Table 4).
The ω-6 PUFA content (% of DW) was generally low in all strains (0.02–1.0% of DW), but differed
significantly among strains. Total ω-6 PUFAs were highest in R. salina (1.0 ± 0.04% of DW),
but were also high in C. mesostigmatica (0.53 ± 0.01% of DW) and G. theta (0.56 ± 0.06% of DW)
(Table 4). The total ω-6 content of R. salina was higher than previously reported for freshwater and
brackish cryptophytes [25,35]. Usually, such high amounts of ω-6 are found in brown algae [41].
More specifically, the highest contents of LA (0.6 ± 0.02% of DW) and arachidonic acid (ARA; 20:4ω6,
0.16 ± 0.01% of DW) were found in R. salina. Docosapentaenoic acid (DPA; 22:5ω6) concentrations
were, in general, very low, and highest in R. salina (0.03 ± 0.01% of DW) and P. sulcata (0.04 ± 0.01%
of DW, Table 4). When calculated as daily gain, the highest totalω-6 PUFA was attained in S. major
(43 µg L−1 day−1; Table 3).
Table 4. The ω-6 fatty acid contents (µg FA in mg dry weight) and proportions (%) of the studied
cryptophytes as well as theirω-6:3-ratios. LA = linoleic acid (18:2ω6), ARA = arachidonic acid (20:4ω6),
DPA = docosapentaenoic acid (22:5ω6). Different letters (a–f) denote significant differences (ANOVA
p < 0.05) between strains. The culture collection codes of the cryptophyte strains can be found in Table 1.
Standard deviations for these FAs are shown in Supplemental Table S1.
Species
Totalω-6
µg FA in
mg DW
ω-6% of
All FA
ω-6%
of DW
ω-6/ω-3
Ratio
LA µg
FA in
mg DW
LA% of
ω-6 FAs
ARAµg
FA in
mg DW
ARA% of
ω-6 FAs
DPAµg
FA in
mg DW
DPA% of
ω-6 FAs
Chroomonas mesostigmatica 8.5 d 13.3 b 0.9 b 1:5 e 2.3 b 26.8 g 0.06 a 0.7 f 0.1 d 70.4 a
Guillardia theta 5.6 b 7.7 c 0.6 c 1:9 d 3.3 c 58.4 c 0.03 c 0.5 f 2.1 a 36.8 b
Hemiselmis sp. 4.1 † 4.9 † 0.4 † 1:14 † 2.6 † 62.8 † 0.02 † 0.4 † 1.5 † 35.3 †
Proteomonas sulcata 1.7 a 2.9 e 0.2 d 1:28 c 0.7 a 43.6 e 0.31 b 18.2 a 0.4 b 24.0 c
Rhodomonas salina 10.4 e 19.8 a 1.0 a 1:3 e 5.5 d 53.1 d 1.62 d 15.5 b 0.3 b 2.4 d
Storeatula major 2.2 a 3.5 d 0.2 d 1:23 c 1.7 b 77.3 b 0.22 ab 9.9 c 0.03 d 1.5 d
Teleaulax acuta 0.2 c 0.7 g 0.02 e 1:126 a 0.1 a 34.9 f 0.01 c 4.9 d 0.01 d 0.01 e
Teleaulax amphioxeia 1.0 a 2.3 f 0.1 d 1:36 b 0.9 a 89.6 a 0.03 c 3 e 0.01 d 0.01 e
† Could not be statistically tested.
Modern western diets are deficient in ω-3 PUFAs, but have excessive amounts of ω-6. Thus,
supplemental products are needed for amending the highω-6/ω-3 ratios. In the studied cryptophytes,
the lowest ω-6/ω-3 ratio was found in T. acuta (1:126) and the highest in R. salina (1:3; Table 4).
These values are well below the suggested dietary ω-6/ω-3 ratio (1-4:1) [11], and substantially lower
than reported for some brown algae (up to 3.8:1) [41]. Thus, despite the surprisingly high ω-6
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PUFA concentrations in some of studied cryptophytes, all of them are suitable for commercial PUFA
production and especially for products that are designed for balancing the dietaryω-6/ω-3 ratios.
2.3. Phytosterols
Three different phytosterols (crinosterol, brassicasterol, and stigmasterol) were found in the
studied cryptophytes (Table 5). Crinosterol and brassicasterol are known to act as anti-ageing
factors [42], whereas stigmasterol is reported to be most valuable of the phytosterols and have
anti-inflammatory effects, preventing, for example, osteoarthritis [15,17]. In general, the total
sterol concentrations were low in the studied cryptophytes (0.09 ± 0.04% of DW), and only
C. mesostigmatica contained all of the three observed sterols (Table 5). Thus, the daily gains were
low (range 0.37–4.36 µg L−1 day−1; Table 3). The obtained results are in line with the ones reported
for diatoms (total sterols 0.06–0.57% of DW) [43], but significantly lower than reported for seaweeds
(0.6–2.3% of DW) [44]. This suggests that the studied cryptophytes—or perhaps algae in general—are
not suitable for profitable sterol production. However, due to the general benefits of phytosterols in
human health, even low sterol contents may improve their value as ingredients for functional foods or
nutraceuticals [15,16].
Table 5. The sterol contents (µg sterol in mg dry weight) of the studied cryptophytes. Different letters
(a–e) denote significant differences (ANOVA p < 0.05) between strains. The culture collection codes of
the cryptophyte strains can be found in Table 1.
Species Crinosterol µgste in mg DW
Brassicasterol µg
ste in mg DW
Stigmasterolµg
ste in mg DW
Sum of Sterols µg
ste in mg DW
Chroomonas mesostigmatica 0.93 a 0.02 c 0.33 a 1.28 a
Guillardia theta nd 0.31 b 0.36 a 0.67 c
Hemiselmis sp. 0.43 † 1.11 † nd 1.54 †
Proteomonas sulcata nd 0.71 a nd 0.71 bc
Rhodomonas salina 0.14 c 0.84 a nd 0.98 ab
Storeatula major 0.24 c 0.72 a nd 0.96 ab
Teleaulax acuta nd 0.35 b nd 0.35 e
Teleaulax amphioxeia 0.45 b nd nd 0.45 d
nd = not detected. † Could not be statistically tested.
3. Materials and Methods
3.1. Growth Rate and Biomass Production
The eight marine cryptophyte strains (Table 1) were grown in F/2 medium in 400 mL plastic
tissue culture flasks. Each strain had two replicates, which were kept at 15 ◦C and under a
14 h:10 h light/dark cycle at a light level of 50 µmol quanta s−1 m−2. The growth rates were calculated
for the exponential growth phase using three sampling points and Equation (1). Biomass production
(as mg dry weight L−1 day−1) of the cultures was determined from freeze-dried samples taken at the
time of lipid sampling near the end of the exponential growth phase.
µ = ln(cellsTx/cellsT0) (1)
3.2. Lipid Extraction
The samples for lipid analyses were collected by centrifugation (3200 rpm for 10 min) near the
end of the exponential growth phase. The obtained pellets were placed into −80 ◦C until freeze-drying.
The lipids were extracted from the freeze-dried samples no longer than three weeks after the sampling.
Two replicates of homogenized biomass samples (1–3 mg) were extracted using chloroform/methanol
2:1 (by vol). Samples were sonicated for 10 min to maximize extraction results, after which samples
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were vortexed and centrifuged for 5 min at 2000 rpm. The liquid part was divided into two equal parts,
one of which was used for fatty acid analysis and the other for sterol analysis.
3.3. Fatty Acid Transesterification and Analysis by GC-MS
Toluene and 1% sulfuric acid in methanol were used for the transesterification of fatty acid methyl
esters (FAME). The samples were heated at 90 ◦C for 90 min, after which 1.5 mL of 2% of KHCO3 and
2 mL hexane was added. The tubes were vortexed and centrifuged (2 min at 1500 rpm) and the upper
layer was collected for analysis. FAMEs were analyzed with a gas chromatograph (Shimadzu Ultra,
Kyoto, Japan) equipped with mass detector (GC-MS), using helium as a carrier gas and an Agilent®
(Folsom, CA, USA) DB-23 column (30 m × 0.25 mm × 0.15 µm). Fatty acids were identified by the
retention times (RT) and using specific ions [24]. All of the detected fatty acids and their concentrations
(as in µg FA in mg DW) in the studied cryptophyte strains are shown in Supplementary Table S1.
3.4. Silylation of Sterols and Analysis by GC-MS
The extracted lipids were diluted in 100 µL of pyridine and silylated with 70 µL of N,O-
bis[trimethylsilyl trifluoroacetamide] (BSTFA), trimethylchlorosilane (TMCS) at 70 ◦C. Trimethylsilyl
(TMS) derivatives of sterols were analyzed with GC-MS (Shimadzu) equipped with A Phenomenex
(Torrance, CA, USA) ZB-5 Guardian column (30 m × 0.25 mm × 0.25 µm). Sterols were identified
using characteristic ions [45].
3.5. Statistics
The differences between the growth rates and lipid production between the cryptophyte strains
were studied with ANOVA and Tukey’s honestly significant difference (HSD) post hoc test. Levene’s
test was used for testing the homogeneity of variances. All the statistical analyses were performed
using R (stats packages: AOV, and TukeyHSD functions) [46] or IBM SPSS Statistics 22 for Windows
(IBM Corp., Armonk, NY, USA).
4. Conclusions
The increasing interest in exploiting microalgae as a source of commercial products with positive
health effects has led to an ongoing search for high production potential of, e.g., essential lipids. In this
study we focused onω-3 andω-6 PUFAs as well as sterol production by eight marine cryptophytes.
Cryptophytes do not have a recalcitrant cell wall, and, thus, they are easier to break and process
further for commercial purposes than many of the already commercially employed algae. In addition,
the cultivation of marine species for nutritional purposes can utilize non-arable lands and water
resources considered unsuitable for agriculture or direct human consumption. We conclude that the
marine cryptophytes offer a great source of EPA, DHA, and other ω-3 PUFAs, and that, in comparison
to freshwater species, marine cryptophytes have more DHA. We found that cryptophytes also produce
ω-6 PUFAs, but their proportion is low compared to that ofω-3 PUFAs, which is beneficial especially
for dietary products targeted to lowerω-6/ω-3 ratios. When considering both the biomass yield and
the yield of the lipids, C. mesostigmatica was the most promising strain for EPA production, whereas
S. major seems promising for both EPA and DHA production. These two strains also had the highest
sterol gains. However, the purpose of this study was not to optimize growth conditions, and, thus,
the other studied strains could likely show even higher growth rates and biomass and lipid yields
under optimized conditions.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/16/1/3/s1, Table S1:
Fatty acid profiles of the studied cryptophyte strains. Concentrations are in µg FA in mg DW (± is for
standard deviations).
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